Ломатин Ю. М. Антиангинальная терапия больных стабильной стенокардией: фокус на снижение частоты сердечных сокращений. Кардиоваскулярная терапия и профилактика. 2006;5(7):86-90.
1. Diaz A., Bourassa M.G., Guertin M-C., et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-74.
2. Patel S.R., Breall J.A., Diver D.J., et al. Bradycardia is associated with development of coronary collateral vessels in humans. Coron Artery Dis 2000; 11:467-72.
3. Heidland U.E., Strauer B.E. Left ventricular muscle mass and eleva ed heart rate associated with coronary plaque distruption. Circulation 2001; 104: 1477-82.
4. Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341-81.
5. Recommendation of the Task Force of the European Society of cardiology. Management of stable angina pectoris. Eur Heart J 1997; 18: 394-413.
6. Thadani U. Treatment of stable angina. Curr Opin Cardiol 1999; 14: 349-58.
7. Expert consensus document on b-adrenergic receptor blockers. The Task Force on Beta-Blockers of the European Society of cardiology. Eur Heart J 2004; 25: 1341-62.
8. Purcell Y., Fox K. Selective and specific If inhibition: new perspectives. Medicographia 2005; 27: 51-5.
9. Daly CA, Clements F, Lopez Sendoz JL, et al. The initial manage8 ment of stable angina in Europe, from the Euro Heart Survey. Eur Heart J 2005; 26: 1011822.
10. Daly C.A., Clements F., Lopez Sendoz J.L., et al. The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina. Eur Heart J 2006; 27: 1298-304.
11. Tendera M. If inhibition: from pure heart reduction to treatment of stable angina. Eur Heart J 2005; Suppl. H: H3-6.
12. Borer J.D., Fox K., Jalion P., et al. Antianginal and antiischemic effects of ivabradin, an If inhibitor in stable angina. Circulation 2003; 107: 817-23.
13. Ruzyllo W., Ford I., Tendera M., et al. Antianginal and antiischemic effects of If current inhibitor ivabradine compared to amlopdipine as monotherapy in patients with chronic stable angina: A 3-month randomized, controlled, double-blind, multicenter trial. Eur Heart J 2004; 25: Abstr 867.
14. Tardif J-C., Ford I., Tendera M., et al. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heat J 2005; 26: 2529-36.
15. Tardif J-C., Fox K., Tendera M., et al. Absence of rebound phenomenon after abrupt discontinuation of ivabradine, a new selective and specific If inhibitor, in patients with coronary artery disease. Eur Heart J 2005; 26: 580.
16. Diaz A., Tardif J-C. Clinical applications of exclusive heart rate reduction in emergence cardiology. Medicographia 2005; 27: 82-6.
